Experienced across a broad spectrum of technologies, including chemical compounds, mechanical devices, biotechnology, software, hardware, and more, Bob is particularly experienced in litigating patents in the life sciences sector, arguing cases involving life-changing drugs, medical devices, and biotech and diagnostic inventions. For example, he was a member of the Fish & Richardson team that prevailed for client Gilead in a case in which Merck claimed Gilead’s groundbreaking hepatitis C drugs Sovaldi® and Harvoni® infringed its patents and sought $2 billion in damages.
Bob’s work also includes patent counseling, advising on patent protection strategy, IP licensing deals, and patent due diligence. He provides patentability, infringement, and freedom to operate opinions for client companies, executives, engineers, and scientists, and conducts due diligence investigations and patent value and strength assessments for venture capitalists and private equity firms considering investing in the sector.
Clients appreciate Bob’s business-centered approach. Whether litigating a case or advising on a patent or business opportunity, Bob offers guidance based on both the client’s current situation and its long-term aspirations.
Before joining Fish, Bob earned a master’s in biology, was a biologist at the Louis Berger Group (2004-2005), and worked in the legal department of Johnson & Johnson (2006).
